|
|
||||||
BDSI News
Current Press Releases
Archived Press Releases:
2007
- BDSI Exercises Option to Acquire U.S. BEMA™ Rights (September 10, 2007)
- BDSI Secures U.S. Commercial Partnership for BEMA™ Fentanyl with Meda AB (September 5, 2007)
- BDSI Names David Blum, M.D. Vice President of Medical Affairs and Clinical Research (August 14, 2007)
- BEMA™ Fentanyl NDA Submission Remains on Target for Third Quarter Following Meeting With FDA (July 2, 2007)
- BDSI Joins Russell Microcap Index (June 26, 2007)
- BDSI to Voluntarily Withdraw Boston Stock Exchange Listing (June 22, 2007)
- BDSI Announces
Positive Key Secondary Efficacy Endpoint Results
For BEMA™ Fentanyl (May 14, 2007) - BEMA™ Fentanyl Demonstrates Substantial Transmucosal Delivery In Absolute Bioavailability Study (May 7, 2007)
- BDSI Announces Positive Phase III Clinical Trial Results for BEMA™ Fentanyl (April 25, 2007)
- BioDelivery Sciences Names Al Medwar as Vice President of Marketing (April 10, 2007)
- BDSI to Present on BEMA™ Fentanyl at American Society of Clinical Pharmacology and Therapeutics 2007 Annual Meeting (March 21, 2007)
- BDSI to Present on BEMA Fentanyl at Oppenheimer Pain Conference (March 2, 2007)
- BDSI Anticipates Announcing Phase III BEMA Fentanyl Efficacy Data in April (February 8, 2007)
- BDSI Announces FDA Acceptance of Bioral® Amphotericin IND (February 2, 2007)
- Hopkins Capital Group II Converts BDSI Series B Preferred Stock at $4.25 per Share (January 12, 2007)
2006
- BDSI to Present at The PIPEs Conference 2006 at the Waldorf Astoria, New York City, November 7-8, 2006 (November 6, 2006)
- BDSI Receives Approval to Restart BEMA™ Fentanyl Trials in California (September 26, 2006)
- Following FDA Meeting BDSI Projects Submission of BEMA™ Fentanyl NDA in Second Quarter 2007 (September 20,2006)
- BioDelivery Sciences Claims Recent Actions by Clinical Development Capital Undermine All Other Stockholders’ Interests (September 5, 2006)
- BioDelivery Sciences Appoints Thomas W. D’Alonzo to Board of Directors (August 30, 2006)
- BioDelivery Sciences Mourns the Loss of Revered Board Member Bill Stephenson (August 29, 2006)
- BEMA™ LA Achieves Therapeutic Plasma Concentrations in Phase I Trial: Complementary Pain Therapy to Phase III BEMA™ Fentanyl Product (August 16, 2006)
- Study Shows Bioral® Delivery Technology Delivers Influenza siRNA Therapeutic and Reduces Virus Levels by 200 times in Mice (August 9, 2006)
- BioDelivery Sciences International and MEDA AB Announce European Licensing Agreement on BEMA™ Fentanyl (August 3, 2006)
- BDSI Announces Purchase of Non-U.S. BEMA™ Technology from QLT USA, Inc. (August 3, 2006)
- BDSI Submits Two Emezine® Pharmacokinetic Study Designs to the FDA Under Special Protocol Assessment (July 17, 2006)
- BioDelivery Sciences Announces Promising Results of Meeting With FDA On Emezine® (June 09, 2006)
- BioDelivery Sciences Demonstrates Multiple Dose Linearity with BEMA™ Fentanyl (May 22, 2006)
- BioDelivery Sciences Closes $7 Million Value Transaction with
Clinical Development Capital, LLC (May 17, 2006) - BioDelivery Sciences Confirms Dose Proportionality with BEMA™ Fentanyl (April 24, 2006)
- BioDelivery Sciences Announces Year End Results (March 31, 2006)
- BioDelivery Sciences Updates Product Development Pipeline Status
and 2006 Milestones (March 14, 2006) - BioDelivery Sciences to Host Conference Call to Discuss Emezine® Status and Provide Update on Product Development Pipeline (March 3, 2006)
- BioDelivery Sciences Receives Non-Approvable Notification from FDA on Emezine® (March 1, 2006)
- BioDelivery Sciences Receives Initial $2 Million Payment from CDC for Development of BEMA(TM) Fentanyl (February 16, 2006)
- BioDelivery Sciences Retains Addison Whitney as Brand Development Firm for BEMA™ and BEMA™ Fentanyl (February 2, 2006)
- BioDelivery Sciences Retains The Investor Relations Group of New York (January 13,2006)
- BioDelivery Sciences Hires Proven Pharmaceutical Executive To Head Sales and Marketing Effort (January 9, 2006)
- BioDelivery Sciences Files IND for BEMA LA, a Treatment for Moderate to Severe Pain (January 6, 2006)
2005
- New Study Shows BDSI's Emezine(R) Demonstrates More Efficient Absorption (December 7, 2005)
- BDSI Announces its Intention to Proceed with Phase III Trials in 2006 on its Second BEMA(TM) Product (November 28, 2005)
- BioDelivery Sciences International to Present at Wall Street Analyst Forum (November 21,2005)
- BDSI Announces Supply Agreement Relating to BEMA(TM) Fentanyl (November 8, 2005)
- BDSI Prepares For Phase III with BEMA(TM) Fentanyl Following Positive Results (November 1, 2005)
- BDSI Closes Public Offering of 4.4 Million Shares (October 5, 2005)
- BDSI Prices Public Offering of 4.4 Million Shares (September 30, 2005)
- BDSI Announces Director Resignations (September 16, 2005)
- BDSI Names Mark Sirgo as Chief Executive Officer (August 23, 2005)
- BDSI Announces Acceptance of Emezine(R) NDA for Review By FDA (July 20, 2005)
- BDSI Secures $7 Million Financing Commitment For Development of BEMA(TM) Fentanyl (July 18, 2005)
- BDSI Secures Additional $2.5 Million Financing With Laurus Master Fund (June 3, 2005)
- BDSI Announces Submission of NDA for Emezine (May 2, 2005)
- William S. Poole Appointed to BDSI Board (April 29, 2005)
- BDSI Announces Relocation of its Corporate Headquarters (March 28, 2005)
- Expediting Drug Development Using Patented Drug Delivery Technologies (March 23, 2005)
- BDSI Announces Its Intention to Initiate Phase III Clinical Trials of BEMA Fentanyl (March 07, 2005)
- BDSI Secures $2.5 Million Financing With Laurus Master Fund (February 23, 2005)
- BDSI Completes Clinical Trials for its Formulation of Emezine(February 9, 2005)
- Sirgo Appointed President of BDSI (January 31, 2005)
- BDSI Announces Agreement to License its Nanocochleate Delivery Technology to Sigma-Tau (January 20, 2005)
- BDSI's Bioral Drug Delivery Technology May Reduce GI Damage Caused By NSAIDs and Aspirin (January 4, 2005)
2004
- Bioral™ Delivery Technology may reduce GI Toxicity of NSAIDS and Aspirin without Dependence on Selective COX-2 Inhibitors (December 22, 2004)
- BDSI to Continue Listing on Nasdaq Small Cap Market (December 1, 2004)
- BDSI Reports Financial Results for the Third Quarter Ended September 30, 2004 (November 12, 2004)
- BDSI Granted NASDAQ Exception for Continued Listing on the Small Cap Market (October 14, 2004)
- BDSI Announces Letter of Intent for License of its Nanocochleated Delivery Technology with Sigma-Tau and Receipt of Initial $250,000 Deposit (September 27, 2004)
- BDSI Elevates Sirgo and Finn to New Positions (September 14, 2004)
- BDSI Announces $2,500,000 Asset Sale to Accentia (September 8, 2004)
- BDSI Announces Final Equity Line of Credit Agreement (September 7, 2004)
- BDSI Announces New Agreement with Hopkins Capital Group (August 24, 2004)
- BDSI Announces the Closing of the Arius Pharmaceuticals Acquisition (August 24, 2004)
- BDSI Announces the Acquisition of Arius Pharmaceuticals, Inc. (August 10, 2004)
- BDSI Receives NASDAQ Delisting Notice and will Appeal (August 3, 2004)
- BDSI Announces $4,000,000 Credit Facility (August 3, 2004)
- BDSI Announces Proposed Licensing Agreement with Sigma-Tau S.p.A. (July 28, 2004)
- Wall Street Journal Reports BDSI Enters into Licensing Agreement for Topical Version of Amphotericin B (July 14, 2004)
- BDSI at the Milano Tech 2004 Technology Partnering Conference Milano, Italy – May 19-20, 2004 (May 12, 2004)
- BDSI at Nanobiotech Conference in San Francisco (April 15, 2004)
- BDSI Announces Licensing of its Topical BioNasal™ Amphotericin B for Chronic Sinusitis (April 13, 2004)
- BDSI Announces Participation at the Nanobiotech Conference in San Francisco (April 6, 2004)
- BDSI Reports 2003 Results (April 6, 2004)
- BDSI in Exclusive Negotiations with Affiliate of Italy’s Sigma-Tau to Formulate New Type of Aspirin (February 11, 2004
- BDSI Updates Public on Spin Off Subsidiary (January 16, 2004)
2003
- BDSI Announces Agreement with Defiante Farmaceutica Lda (December 3, 2003)
- BDSI to Establish Israeli Subsidiary to Develop Oral Enzyme Replacement for Gauchers Disease (November 24, 2003)
- BDSI Announces Plans to Distribute Interests in Food Processing and Personal Care Product Subsidiary to Stockholders (November 19, 2003)
- BDSI to Participate in BioMilano 2003 (November 11, 2003)
- New Biogeode Cochleates could make Healthy Nutrients more Available in Processed Foods (September 30, 2003)
- Bioral™ Pharmaceutical Delivery System Improves Efficacy and Reduces Side Effects of Aspirin (September 23, 2003)
- BDSI Formulates Omega-3 Fatty Acids as Stable, Dry Powder Using its Bioral Nanotechnology (June 30, 2003)
- BDSI Announces Common Stock Repurchase Program (April 2, 2003)
- BDSI Reports 2002 Results (April 1, 2003)
- BDSI Announces Formation of Subsidiary to Develop Opportunities in the Processed Food and Beverage Sectors (February 26, 2003)
- BDSI Announces Licensing Agreement with PPD (January 6, 2003)
 |
Copyright © 2008 BioDelivery Sciences International, Inc. All Rights Reserved.
|